ArticleIJID regions2025
Predicting 7-day mortality in COVID-19 pneumonia: performance of NEWS2, qSOFA, and CRB-65 and development of the CCP-7 prediction scores.
Article in IJID regions, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Effective early risk stratification of COVID-19 pneumonia patients in emergency departments (EDs) is crucial, especially in resource-limited settings. Common clinical scores (National Early Warning Score version 2 [NEWS2], quick Sequential Organ Failure Assessment [qSOFA], and CRB-65) were not developed for COVID-19 and may inadequately predict short-term mortality. This study aimed to evaluate the prognostic performance of these scores and to develop and internally validate a novel score-the Chiang Mai COVID-19 Pneumonia 7-Day Mortality Prediction Score (CCP-7). Methods: We conducted a retrospective cohort study of patients aged ≥16 years presenting to a tertiary ED in Northern Thailand with confirmed COVID-19 pneumonia between January 2020 and December 2023. Demographic, clinical, and laboratory data were extracted from electronic records. The predictive accuracy of NEWS2, qSOFA, CRB-65, and the newly developed CCP-7 score for 7-day mortality was assessed using a regression framework, the area under the receiver operating characteristic curve (AUROC), calibration, and DeLong tests for AUROC comparisons. Results: Among 735 patients included, the 7-day mortality rate was 5.2%. Four variables-respiratory rate greater than 30/min, altered mental status, abnormal white blood cell count, and thrombocytopenia-were independently associated with mortality and incorporated into the CCP-7. The CCP-7 score demonstrated superior discrimination (AUROC, 0.83; 95% confidence interval [CI]: 0.76-0.90) compared to CRB-65 (0.80, 95% CI: 0.74-0.86), NEWS2 (0.77, 95% CI: 0.68-0.85), and qSOFA (0.64, 95% CI: 0.52-0.75). DeLong tests showed no statistically significant differences between CCP-7 and CRB-65 or NEWS2. At a cutoff of ≥3 points, CCP-7 achieved 57.1% sensitivity and 89.4% specificity. Conclusions: CCP-7 is a simple and context-appropriate tool for predicting 7-day mortality in patients with COVID-19 pneumonia. Although it showed numerically higher discrimination than other scores, the differences were not statistically significant. Its reliance on routine ED parameters makes it particularly suited for rapid risk stratification in low-resource settings, but external validation is essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.